What to know about the FDA’s approval of new drug for the treatment of opioid addiction

Prescription opioid abuse and addiction is a global problem, and as of April, more than 300,000 people worldwide were treated for addiction-related problems.

But now, the Food and Drug Administration has approved a new drug, Zyban, that could be the first drug to treat opioid addiction and its complications.

The approval marks a major step toward tackling the problem of addiction to opioids, which is now the leading cause of death among Americans.

Zyban works by helping people develop a tolerance to opioids in their body.

The FDA approved the drug last year and said it could help treat pain, anxiety, depression, anxiety disorder and addiction to other medications.

It could also be used to treat pain and spasticity associated with chronic pain, such as those associated with multiple sclerosis and spinal cord injuries.

The drug was developed by a group of Stanford University researchers.

They were funded by the National Institutes of Health, and the company will receive a $100 million grant.

Zyben is a derivative of a synthetic opioid called naloxone, which can reverse an overdose from an opioid overdose.

The drug is currently approved in Canada, but it will soon be approved in the U.S.

The FDA is also expected to announce approval of another drug that is made by a company called Narcan.

This drug can reverse the effects of an opioid drug overdose, and it has already been used to revive people with heart failure.

Narcan, which has a similar molecular structure to nalapropin, is approved in two countries, India and the U of T, where it was developed.

Narcan is an antidote to opioids and other painkillers, and is approved for use in the treatment or prevention of opiate overdose in humans.

The DEA’s decision to approve Zyban comes as the agency’s own opioid program is facing major criticism.

A recent report by the Drug Policy Alliance called the agency a “failed leader” and said that its opioid programs were not delivering the drugs they were promised.

The DEA said the agency was not able to identify the “real reasons” for the opioid abuse crisis, but said the problems were caused by a lack of data and poor management.